Online inquiry

IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2538MR)

This product GTTS-WQ2538MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2538MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9620MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ15541MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ14924MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ67MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ5729MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ9560MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ1543MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ3398MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW